H. Lundbeck A/S (0ND5.IL)

39.10 +0.11 (+0.29%) 收市：05:33PM BST

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 5,600

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Joerg Hornstein	CFO & Exec. VP of Corp. Functions	3.4M	無	1977
Mr. Jacob Tolstrup	Exec. VP of Commercial Operations	8.2M	無	1972
Mr. Lars Bang	Exec. VP of Product Devel. & Supply	7.7M	無	1962
Dr. Per Johan Luthman	Exec. VP of R&D	8.6M	無	1959
Mr. Charl van Zyl	Pres & CEO	無	無	1967
Dr. Tarek Samad Ph.D.	Sr. VP & Head of Research	無	無	無
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	無	無	無
Ms. Elise Hauge	Exec. VP of People & Communication	無	無	1967
Mr. Ole Chrintz	Sr. VP of International Markets	無	無	1958
Mr. Keld Flintholm Jorgensen	Exec. VP of Corp. Strategy & Bus. Devel.	無	無	1971

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 DKK。

描述

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

公司管治

截至 2023年10月1日 止，H. Lundbeck A/S 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：4；董事會：3；股東權利：9；現金賠償：2。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。